Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 28976863

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2017 Oct 5
First author
Marcus R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2017 Oct 5;377(14):1389-1390. doi: 10.1056/NEJMe1706154.
    note
    Source null
    related pmid
    28976852
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Dec 28;377(26):2605. doi: 10.1056/NEJMc1714337.
    note
    Source null
    related pmid
    29281573
    relationship
    Comment in

Authors and identifiers

  1. name
    Marcus R
    type
    Author
  2. name
    Davies A
    type
    Author
  3. name
    Ando K
    type
    Author
  4. name
    Klapper W
    type
    Author
  5. name
    Opat S
    type
    Author
  6. name
    Owen C
    type
    Author
  7. name
    Phillips E
    type
    Author
  8. name
    Sangha R
    type
    Author
  9. name
    Schlag R
    type
    Author
  10. name
    Seymour JF
    type
    Author
  11. name
    Townsend W
    type
    Author
  12. name
    Trněný M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Marcus R
    type
    Author
  2. name
    Davies A
    type
    Author
  3. name
    Ando K
    type
    Author
  4. name
    Klapper W
    type
    Author
  5. name
    Opat S
    type
    Author
  6. name
    Owen C
    type
    Author
  7. name
    Phillips E
    type
    Author
  8. name
    Sangha R
    type
    Author
  9. name
    Schlag R
    type
    Author
  10. name
    Seymour JF
    type
    Author
  11. name
    Townsend W
    type
    Author
  12. name
    Trněný M
    type
    Author
bibliography ids
  1. nci-bib-4ff00f773ae821eba96a31a1
book metadata
content sha256
2d26b0c2a256edc62f808b02ba08cd1bf1bfb7dd078df87f25dac8700d6e235d
document type
citation
dois
  1. 10.1056/NEJMoa1614598
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:28976863
immutable id
pubmed:28976863@2d26b0c2a256edc62f808b02ba08cd1bf1bfb7dd078df87f25dac8700d6e235d
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
14
name
The New England journal of medicine
nlm unique id
0255562
pages
1331-1344
volume
377
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2017 Oct 5;377(14):1389-1390. doi: 10.1056/NEJMe1706154.
    note
    Source null
    related pmid
    28976852
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Dec 28;377(26):2605. doi: 10.1056/NEJMc1714337.
    note
    Source null
    related pmid
    29281573
    relationship
    Comment in
outcomes validated
false
pmid
28976863
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
0ba1c6ca07b9504a1a7d6ae26ce01191cc7f61fc34182f9bcd6c0307747c8e63
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct 5
precision
day
year
2017
publication types
  1. Comparative Study
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28976863/
title
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Preserved source evidence · Independent clinical review pending · Not medical advice